What Are the Side Effect Profiles for Modern AML Treatments?

Published on

Topics include: Treatments and Treatment | General

What potential side effects can acute myeloid leukemia (AML) patients expect from new, powerful therapies? Have modern AML treatments become less toxic? Noted expert, Dr. Ross Levine from Memorial Sloan Kettering Cancer Center, discusses recently approved medicines and their unique side effect profiles, and explains how they compare to traditional chemotherapy. Watch now to learn more about new AML treatment options and their side effects. 

This is a Patient Empowerment Network program produced by Patient Power, in partnership with The Leukemia & Lymphoma Society (LLS). We thank Astellas, Celgene Corporation, Novartis, Pfizer and Seattle Genetics for their support.

View more programs featuring and

Produced in association with and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:          

Let’s talk about some of the side effects. You mentioned these new approved therapies. These are powerful medicines. I know it’s going to vary. But what are some of the things I’m dealing with, not from the disease, but from the medicine?

Dr. Levine:                  

Well, it’s a great question. And it’s different for the different medicines. The liposomal form of chemotherapy still has a lot of the side effects of chemotherapy. They’re just a little bit better tolerated. You still can lose your hair. You can still get low counts and mouth sores, but it’s all better. But what I’m most excited about are the drugs, again, say IDH2, a drug called IDHIFA for the 5 to 10 percent of patients who have the IDH2 mutation. It’s a pill. And you can take it. And you can be at home. And, in general, there are modest, at most, side effects. You might get a little swelling. 

You might, in the first couple of weeks, feel a little off. But after a month or two, people feel quite good. And there are other leukemias, CML being an example, with imatinib (Gleevec) and sons of Gleevec, CLL now with a drug called ibrutinib (Imbruvica) where people can take pills that are directed against specific genetic blue print events in the leukemia.

And they take that pill, and the side effect profile is vastly different than what we’re used to with chemotherapy and transplant. So, we’re just beginning that era of smarter, more effective, and less toxic treatment.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Genetic Profiling: Identifying High-Risk and Low-Risk AML Patients

What can you learn about your AML condition from your genetic profile? AML expert Dr. Ross Levine joined us at ASH 2017 to share the latest research on how molecular characterization affects AML prevention, progression and treatment.

Published:

How to Test for, Identify and Treat AML Subtypes

How many subtypes of AML are there? Are you getting the right testing done? AML expert Dr. Ross Levine joined us at ASH 2017 to discuss testing for subtypes and an individualized approach to treatment.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on May 24, 2018